C.J. Schinkel PhD

Medical Specialist
Main activities
Patient care, Research, Other
Medical Microbiology / Clinical Virology (MD PhD)
Focus of research

Most of my research since my PhD in 2008 has focused on hepatitis C virus (HCV), which has resulted in a current productive research line, encompassing several aspects of HCV infection – from epidemiology to clinical and fundamental virological research - and which is embedded in a multidisciplinary network of institutional, national and international collaborations.

I have been involved in several phase 1 and 2 trials with protease inhibitors or other candidate drugs. These clinical trials led to several virological ancillary studies, styding HCV resistance to direct acting antivirals. 

A second research topic has been the new HCV epidemic in HIV infected MSM. Together with Prof. Dr. Prins, from the Public Health Service from Amsterdam in 2008 we successfully applied for a grant from the AIDS Fund to start the MOSAIC cohort, a multicenter cohort with the objective to study the sequellae of acute Hepatitis C virus (HCV) infection in this patient group.An interesting novel observation within this cohort was the partial immunity we observed against reinfection with the same genotype. To investigate this further we started a collaboration with Prof. Spits and Dr. Beaumont from AIMM therapeutics, with the ultimate goal of developing monoclonal antibodies against HCV (funded by the dutch government)

To obtain a more comprehensive understanding of protective immunity against HCV, transcriptomics, innate immunity and T-cell responses in the same frequently exposed non-chronic drug users from the ACS will be studied by groups we collaborate with (the group o Dr. Boonstra from the Erasmus Medical Center in Rotterdam).
Besides the topics described above I also initiated and participated studies on the molecular epidemiology of HCV. Part of this work has been done in collaboration with Prof. Pybus from Oxford University and part with Dr. T van der Laar, from the Free University of Amsterdam.

Key publications
  • van der Valk Marc, Zaaijer Hans L., Kater Arnon P., Schinkel Janke Sofosbuvir shows antiviral activity in a patient with chronic hepatitis E virus infection Journal of hepatology 2017;66 (1):242-243 [PubMed]
  • Vanhommerig Joost W., Thomas Xiomara V., van der Meer Jan T. M., Geskus Ronald B., Bruisten Sylvia M., Molenkamp Richard, Prins Maria, Schinkel Janke, Arends J., van Baarle D., van den Berk G., Brinkman K., Coutinho R., van den Ende M., Grady B., Gras L., Ho C., Kwa D., van de Laar T., Lambers F., Mulder J., Reesink H., Smit C., van der Valk M., van der Veldt W., Karlas J., Bakker M., Visser G., Buswell C. Hepatitis C virus (HCV) antibody dynamics following acute HCV infection and reinfection among HIV-infected men who have sex with men Clinical infectious diseases 2014;59 (12):1678-1685 [PubMed]
  • Markov Peter V., van de Laar Thijs J., Thomas Xiomara V., Aronson Sem J., Weegink Christine J., van den Berk Guido E., Prins Maria, Pybus Oliver G., Schinkel Janke Colonial History and Contemporary Transmission Shape the Genetic Diversity of Hepatitis C Virus Genotype 2 in Amsterdam Journal of virology 2012;86 (14):7677-7687 [PubMed]
  • Lambers Femke A. E., Prins Maria, Thomas Xiomara, Molenkamp Richard, Kwa David, Brinkman Kees, van der Meer Jan T. M., Schinkel Janke, Countinho R., Reesink H., van Baarle D., Smit C., Gras L., van der Veldt W. Alarming incidence of hepatitis C virus re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV-infected MSM AIDS (London, England) 2011;25 (17):F21-F27 [PubMed]
  • Jansen Rogier R., Wieringa Joanne, Koekkoek Sylvie M., Visser Caroline E., Pajkrt Dasja, Molenkamp Richard, de Jong Menno D., Schinkel Janke Frequent detection of respiratory viruses without symptoms: toward defining clinically relevant cutoff values Journal of clinical microbiology 2011;49 (7):2631-2636 [PubMed]
All Publications
Curriculum Vitae

Dr. Janke Schinkel, MD PhD
Date and place of birth: 1- 10 – 1966, Ten Boer
Nationality: Dutch
Civil status: married, two children

Masters degree

  • Medicine, Free University, Amsterdam, The Netherlands (1986 – 1995)
  •  Date 30/06/1995

Work experience since obtaining Masters degree

  • since 2008 Head of Laboratory of Clinical Virology, Academic Medical Center, Amsterdam
  • 2004 – 2008 Staff Clinical Virologist, Academic Medical Center, Amsterdam
  • 1998 – 2004 Resident Medical Microbiology & PhD researcher, Leiden University Medical Center
  • 1997 – 1998 Clinical Research Fellow Amsterdam Cohort Studies on HIV/AIDS, Public Health Service, Amsterdam
  • 1996 – 1997 Senior House Officer in Internal Medicine in the United Kingdom
  • 1995 – 1996 Residencies in Internal Medicine & Cardiology


  • Leiden University
  • Date (22/10/2008)
  • May 2006: internship Oxford with Prof. O. Pybus on modeling HCV evolution
  • Supervisor (‘Promotor‘): Prof. W. Spaan
  • Title of thesis: Genetic variability of hepatitis C virus: relevance to treatment outcome and course of infection
  • Registration as a specialist (16/07/2004)

Grants & Scholarships:

  • 2013 AIDS fund grant (co-applicant): Acute HCV infections and reinfections in HIV-infected MSM
  • 2011 partner in Virgo / FES Consortium. WP5.3 Chronic Viral Hepatitis Novel Interventions: Neutralizing antibodies that protect against HCV reinfection
  • 2010 BBMRI-NL (Biobanking and Biomolecular Resources Research Infrastructure. Measurement of longitudinal HCV loads in HCV seroconverters from the Amsterdam Cohort Studies on drug users
  • 2008 AIDS fund grant (co-applicant) Sequellae of acute Hepatitis C virus infection among HIV-infected individuals: the HIV/HCV primo cohort
  • 2003 ‘doelmatigheids’ study funded by the Leiden University Medical Center.  Funding for a clinical fellow for 2 years to study the diagnosis of external drainage-related bacterial meningitis
  • 2001 Young Investigator Bursary from the European Association for the Study of the Liver (EASL)
  • 1992 Erasmus Scholarship, Leeds, UK
  • 1990 Dr. Hendrik Muller’s National Fund


  • inventor of parechovirus type 4, patent number 06783845.8 - 2405, European Patent Office
  • inventor HCV antibodies: V.O. ref: P102716EP00 European patent application No. 14183805.2

PhD supervision:

  • Rogier Jansen, MD, clinical microbiologist. Project: clinical relevance of the molecular detection of respiratory pathogens. PhD graduation 2014 (co-promotor)
  • Xiomara Thomas, MSc. Project: HCV virus evolution and the presence of neutralizing antibodies. PhD graduation march 13th., 2015 (co-promotor)
  • Cynthia Ho, Msc. Project: ultradeep sequencing of HCV variability: the interplay of virus and host. PhD graduation 2015 (co-promotor)
  • Joost van Hommerig, Msc. Project: HCV infection among HIV positive MSM. PhD graduation 2015.
  • Sabrina Merat, Msc. Project: humoral immunity against HCV. PhD graduation 2016 (co-promotor)
  • Gaby Steba, MSc: Virological studies on Hepatitis C transmission characteristics. PhD graduation 2017. Copromotor
  • Astrid Newsum: MD, project: The epidemic of hepatitis C (HCV) (re)infection in HIV-infected men who have sex with men: unresolved questions on the interplay between HIV and acute HCV. PhD graduation 2019

Other research related activities:

  • PhD examiner for the University of New-South Wales, Inflammation & Infection Research Centre (IIRC), Sydney Australia (prof. Andrew Lloyd)
  • PhD examiner for the University of Oxford, department of Zoology (Prof. Oliver Pybus)
  • Member of the Laboratory Working Group of INC3: The International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts Study Research (virology representative for the Amsterdam Cohort Studies)
  • Board member of the Dutch Society for Clinical Virology
  • Member of the European Society of Clinical Virology (ESCV)
  • Peer reviewer for the annual ESCV meeting
  • Peer reviewer for the, ‘Nature reviews in Gastroenteroly and Hepatology’, ‘AIDS’ , ‘Hepatology’, ‘Infection, genetics and evolution’, ‘Journal of Clinical Virology’, journal of virologic methods
  • Collaboration with Vertex Pharmaceuticals, Cambridge MA, USA (dr. T. Kieffer, Dr. J. Sullivan)
  • Collaboration with Prof. Andew Lloyd, Univeristy of New-South Wales, Sydney
  • Collaboration with Prof. O. Pybus, University of Oxford, department of Zoology (Prof. Oliver Pybus)
  • Collaboration with Prof. Bill Paxton, University of Liverpool, UK

Oral presentations (selection)

  • Invited speaker at the International Liver Meeting (EASL), Vienna 2015
  • Invited speaker at 18th Annual Resistance and Antiviral Therapy Meeting, London, october 2014
  • Invited speaker at the HIV, HCV and HBV Drug Resistance Workshop (Berlin, june 2014)
  • Invited speaker at symposium “Treatment dilemma’s in HCV Treatment”, Amsterdam, april 2013
  • Invited speaker at the meeting of the European Society of Antiviral resistance on Hepatitis C virus resistance (Vienna, October 2012)
  • Invited speaker at the Mini Symposium ‘Proteaseremmers bij de behandeling van hepatitis C: de toekomst is begonnen’ (2011, 2012). Accredited postgraduate training for microbiologist, infectious disease specialist, hepatologist
  • Invited speaker at the AIGHD symposium “Hepatitis C: Future treatment and prevention’ (Feb. 2012)
  • Invited speaker at the ‘Infectieziekten Symposium AMC “ CMV infectie: Facts and faqs’’ (December 2011)
  • Invited speaker at the autumn meeting of the NVMM/VIZ (nederlandse vereniging voor medische microbiologie / vereniging voor infectieziekten) on HCV reinfection in HIV+ MSMs (Nov. 2011)
  • Invited speaker at the ‘landelijke hepatitis week’ on ‘diagnosis of viral hepatitis’ (May, 2011)
Research programmes

C.J. Schinkel PhD (Towards elimination of Hepatitis C virus)

Current research funding
  • AMC
  • AMC (Vrijgesteld)
  • Amsterdam Inst. for Global Health and Development
  • Gilead Sciences
  • Stichting Aidsfonds/SOA AIDS Nederland
  • ZonMw